Protein-protein interaction inhibitor of SRPKs alters the splicing isoforms of VEGF and inhibits angiogenesis
Open Access
Abstract
No abstract availableKeywords
Funding Information
- University Grants Committee Research Grants Council
This publication has 61 references indexed in Scilit:
- Oncogenic Splicing Factor SRSF1 Is a Critical Transcriptional Target of MYCCell Reports, 2012
- WT1 Mutants Reveal SRPK1 to Be a Downstream Angiogenesis Target by Altering VEGF SplicingCancer Cell, 2011
- Inhibition of Hepatitis C Virus Replication by a Specific Inhibitor of Serine-Arginine-Rich Protein KinaseAntimicrobial Agents and Chemotherapy, 2010
- Rationalizing the chemical space of protein–protein interaction inhibitorsDrug Discovery Today, 2010
- Regulation of Vascular Endothelial Growth Factor (VEGF) Splicing from Pro-angiogenic to Anti-angiogenic IsoformsJournal of Biological Chemistry, 2010
- VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapyBritish Journal of Cancer, 2008
- A Sliding Docking Interaction Is Essential for Sequential and Processive Phosphorylation of an SR Protein by SRPK1Molecular Cell, 2008
- Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanomaBritish Journal of Cancer, 2007
- Utilization of host SR protein kinases and RNA-splicing machinery during viral replicationProceedings of the National Academy of Sciences, 2006
- Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKTNature Structural & Molecular Biology, 2005